alphataxin

Alphataxin is an orally available small-molecule drug developed to increase the number of circulating and tumor-infiltrating CD4+ T cells. It acts as a surrogate for alpha-1 proteinase inhibitor (α1PI, also known as alpha-1 antitrypsin) in pathways that regulate CD4+ T cell formation. Alphataxin has demonstrated preclinical efficacy in murine models of renal cell carcinoma, both as monotherapy and in combination with anti-PD-1 immune checkpoint inhibitors. In these studies, Alphataxin significantly elevated the ratio of CD4+/CD8+ T cells and suppressed tumor growth, with combination therapy leading to complete regression or significant suppression of tumors and elimination of metastasis. The drug’s mechanism involves targeting a pathway regulated by α1PI (A1AT), which is important for immune modulation via effects on Pre-T cell locomotion and helper T cell formation. Alphataxin is being developed primarily for kidney cancer but may have potential applications in other T cell-responsive cancers[1][3][4][7].

Brand names

alphataxin

Other names

alphataxin